Dr. Sarah Wright, D.O.
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
At a glance
- Medical school
- New York College of Osteo Medicine of New York Institute of Technology (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: New York College of Osteo Medicine of New York Institute of Technology
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
DC license DO210001335
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Children's Hospital (212 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Exondys-51 (eteplirsen) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 25 payments worth $23,805 in total to this clinician.
| Sarepta Therapeutics, Inc. | $23,308 |
|---|---|
| Genentech, Inc. | $243 |
| Genentech USA, Inc. | $150 |
| Biogen, Inc. | $104 |
| Consulting Fee | $19,955 |
|---|---|
| Travel and Lodging | $2,669 |
| Food and Beverage | $1,181 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sarepta Therapeutics, Inc. Dec 18, 2025 | Consulting Fee Elevidys · Genetic Disease | $11,815 |
| Sarepta Therapeutics, Inc. May 15, 2025 | Consulting Fee Elevidys · Genetic Disease | $8,140 |
| Sarepta Therapeutics, Inc. Dec 12, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Phoenix, AZ · in-kind | $734 |
| Sarepta Therapeutics, Inc. Dec 13, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Phoenix, AZ · in-kind | $710 |
| Sarepta Therapeutics, Inc. May 9, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Chicago, IL · in-kind | $434 |
| Sarepta Therapeutics, Inc. Dec 12, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Phoenix, AZ · in-kind | $261 |
| Sarepta Therapeutics, Inc. Dec 13, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Phoenix, AZ · in-kind | $255 |
| Sarepta Therapeutics, Inc. May 9, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Chicago, IL · in-kind | $178 |
| Sarepta Therapeutics, Inc. May 21, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Chicago, IL · in-kind | $70.00 |
| Sarepta Therapeutics, Inc. May 21, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Chicago, IL · in-kind | $26.32 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $57,452 in research payments for these studies, mostly to the institutions running them.
- An Open-Label, Single-arm Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Efficacy of Gefurulimab in Pediatric Patients (6 to < 18 years of age) with Generalized Myasthenia Gravis (gMG)…
Alexion Pharmaceuticals, Inc. - Long term follow up study of patients with spinal muscular atrophy receiving risdiplam treatment
Genentech, Inc. - Study name not reported
Sarepta Therapeutics, Inc. - SRP-9001-401
Sarepta Therapeutics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.